Drug Profile
Research programme: anti-cancer therapeutics - Molplex Pharmaceuticals
Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Molplex pharmaceuticals
- Developer Molplex Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Head and neck cancer; Lymphoma
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 Oct 2020 No recent reports of development identified for research development in Head-and-neck-cancer in United Kingdom
- 28 Oct 2020 No recent reports of development identified for research development in Lymphoma in United Kingdom